Cindy has always been active. As a physical education teacher, and later an elementary school principal, she built her career ...

Brensocatib hydrate (Brinsupri; Insmed Inc) launched commercially in Japan on October 19 for adults and children 12 years and ...

Among patients with bronchiectasis, those with purulent vs. mucoid or mucopurulent sputum had higher measures of neutrophil ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Updated clinical guidelines for adult bronchiectasis suggest long-term macrolide or brensocatib therapy to reduce frequent ...

Insmed Incorporated announced the commercial launch in Japan of BRINSUPRI Tablets 25 mg (brensocatib hydrate), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and ...

An abstract using U.S. Bronchiectasis and NTM Research Registry data comparing bronchiectasis in people with and without ...

Insmed (INSM) said Monday that it is launching a 25 mg tablet of Brinsupri in Japan to treat non-cystic fibrosis bronchiectasis, or NCFB, in adults and pediatric patients aged at ...

For years, pulmonologists treating bronchiectasis had little formal guidance and only off-label tools. That has changed in ...

New research in cystic fibrosis rats shows that chronic Pseudomonas aeruginosa lung infection does not hinder lentiviral ...

When examining sphingolipid profiles in patients with idiopathic pulmonary fibrosis and patients with fibrotic ...

Jay N. Yepuri, MD, MS, FACG, is a board-certified gastroenterologist and member of the Digestive Health Associates of Texas Board of Directors and Executive Committee. Liver fibrosis is a condition ...